MajesTEC-3 — Teclistamab in combination with daratumumab subcutaneously (Tec-Dara) versus daratumumab, pomalidomide, and dexamethasone (DPd) or daratumumab, bortezomib, and dexamethasone (DVd) in relapsed or refractory multiple myeloma (MajesTEC-3)

Phase 3 · Multiple Myeloma

Population

Relapsed or refractory multiple myeloma after 1–3 prior lines of therapy, including a proteasome inhibitor and lenalidomide.

Primary Endpoint

Progression-free survival

Rationale

Teclistamab is approved as a single agent after multiple prior lines. MajesTEC-3 tests whether pairing the BCMA×CD3 bispecific with daratumumab earlier in the relapsed setting outperforms today's daratumumab-based triplets, potentially moving T-cell engagers ahead of later-line use.

What It Could Change

Could establish a teclistamab-daratumumab doublet as an earlier-line standard in relapsed/refractory myeloma, ahead of conventional daratumumab triplets.